- Home
- BEN vs BMRN Comparison
BEN vs BMRN Comparison
Compare BEN & BMRN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BEN
- BMRN
- Stock Information
- Founded
- BEN 1947
- BMRN 1996
- Country
- BEN United States
- BMRN United States
- Employees
- BEN N/A
- BMRN N/A
- Industry
- BEN Investment Managers
- BMRN Biotechnology: Pharmaceutical Preparations
- Sector
- BEN Finance
- BMRN Health Care
- Exchange
- BEN Nasdaq
- BMRN Nasdaq
- Market Cap
- BEN 12.1B
- BMRN 11.1B
- IPO Year
- BEN N/A
- BMRN 1999
- Fundamental
- Price
- BEN $23.36
- BMRN $54.65
- Analyst Decision
- BEN Hold
- BMRN Buy
- Analyst Count
- BEN 12
- BMRN 20
- Target Price
- BEN $23.46
- BMRN $92.21
- AVG Volume (30 Days)
- BEN 4.1M
- BMRN 2.2M
- Earning Date
- BEN 11-07-2025
- BMRN 10-28-2025
- Dividend Yield
- BEN 5.47%
- BMRN N/A
- EPS Growth
- BEN N/A
- BMRN 154.69
- EPS
- BEN 0.52
- BMRN 3.40
- Revenue
- BEN $8,638,200,000.00
- BMRN $3,063,608,000.00
- Revenue This Year
- BEN N/A
- BMRN $13.35
- Revenue Next Year
- BEN $4.55
- BMRN $9.18
- P/E Ratio
- BEN $44.67
- BMRN $16.09
- Revenue Growth
- BEN 4.67
- BMRN 18.36
- 52 Week Low
- BEN $16.25
- BMRN $52.48
- 52 Week High
- BEN $26.08
- BMRN $73.51
- Technical
- Relative Strength Index (RSI)
- BEN 43.19
- BMRN 47.87
- Support Level
- BEN $22.69
- BMRN $53.19
- Resistance Level
- BEN $23.89
- BMRN $54.50
- Average True Range (ATR)
- BEN 0.49
- BMRN 1.20
- MACD
- BEN -0.02
- BMRN 0.29
- Stochastic Oscillator
- BEN 42.93
- BMRN 62.43
About BEN Franklin Resources Inc.
Franklin Resources provides investment services for individual and institutional investors. At the end of July 2025, Franklin had $1.617 trillion in managed assets, composed primarily of equity (41%), fixed-income (27%), multi-asset/balanced (11%) funds, alternatives (16%) and money market funds (5%). Distribution tends to be weighted between retail investors (56% of AUM) and institutional accounts (41%), with high-net-worth clients accounting for the remainder. Franklin is one of the more global of the US-based asset managers we cover, with 31% of its assets under management invested in global/international strategies and just as much sourced from clients domiciled outside the United States.
About BMRN BioMarin Pharmaceutical Inc.
BioMarin is a global biotechnology company focused on developing and commercializing therapies for rare genetic diseases. BioMarin specializes in enzyme replacement therapies, gene therapies, and other advanced treatments aimed at addressing complex genetic disorders. The company has eight approved therapies for conditions including achondroplasia, phenylketonuria (PKU), hemophilia, and mucopolysaccharidosis. BioMarin has an expanding, yet relatively early-stage, pipeline of treatments in development.